摘要
目的观察灯盏生脉胶囊治疗不稳定型心绞痛(UAP)的临床疗效。方法选取2015年10月至2018年8月于首都医科大学附属北京中医医院干部保健科收治的150例UAP患者为研究对象,采用随机数字表法分为对照组(n=75)和观察组(n=75)。对照组予常规治疗,观察组在常规治疗基础上加用灯盏生脉胶囊(每粒装0.18 g,2粒/次,3/d),2个月为一疗程。治疗结束后,比较两组患者临床疗效、24 h心肌缺血次数、持续时间及缺血总负荷,血流变学包括全血黏度、血浆黏度、红细胞比容、纤维蛋白原、血沉;分别采用HAMA、HADA和SF-36量表评价患者焦虑、抑郁情况和生活质量,并记录不良反应。结果治疗后,两组患者心肌缺血发作次数、持续时间、缺血总负荷,血流变指标(全血黏度、血浆黏度、红细胞比容、纤维蛋白原、血沉)及HAMA、HADA均较治疗前降低,SF-36量表中生理功能、躯体疼痛、总体健康、活力、精神健康的评分均较治疗前升高,差异均有统计学意义(P<0.05);与对照组相比,观察组心肌缺血持续时间、缺血总负荷、全血黏度、血浆黏度、血沉、HAMA、HADA,SF-36量表中躯体疼痛、活力、精神健康改善更为明显(P<0.05)。观察组患者总有效率为88.9%,显著高于对照组的69.8%(P<0.05)。两组均无明显不良反应出现。结论灯盏生脉胶囊治疗UAP安全且有效。
Objective To observe the clinical efficacy of Dengzhan Shenmai Capsules in the treatment of unstable angina pectoris (UAP). Methods A total of 150 UAP patients admitted to the Department of Health and Welfare of Beijing Chinese Medicine Hospital affiliated to Capital Medical University from October 2015 to August 2018 were enrolled in the study. They were randomly divided into the control group (n=75) and the observation group (n=75). The control group received conventional treatment, and the observation group was given Dengzhan Shengmai capsule (0.18g, 2 capsules/ time, 3 times/d) based on conventional treatment, and the treatment was performed for 2 months. After treatment, the clinical efficacy, 24 h myocardial ischemia, duration and total ischemic load were compared. Hemorheology included whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and erythrocyte sedimentation rate;HAMA, HADA, and SF-36 scales were used to assess anxiety, depression, and quality of life, and adverse events were recorded. Results After treatment, the number of myocardial ischemic attacks, duration, total ischemic load, hemorheological parameters (whole blood viscosity, plasma viscosity, hematocrit, fibrinogen, erythrocyte sedimentation rate) and HAMA, HADA were compared between the two groups. Before the decrease, the scores of physiological function, physical pain, overall health, vitality and mental health in the SF-36 scale were higher than those before treatment (P<0.05). Compared with the control group, the observation was compared. The myocardial ischemia duration, total ischemic load, whole blood viscosity, plasma viscosity, erythrocyte sedimentation rate, HAMA, HADA, SF-36 scale showed more significant improvement in physical pain, vitality and mental health (P<0.05). The total effective rate of the observation group was 88.9%, which was significantly higher than that of the control group (69.8%)(P<0.05). No significant adverse reactions occurred in either group. Conclusions Dengzhan Shenmai Capsules is effective a
作者
贾淑红
王振裕
王燕丽
冯耀辉
谢皛
Jia Shuhong;Wang Zhenyu;Wang Yanli;Feng Yaohui;Xie Xiao(Department of Cadre Health, Beijing Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China)
出处
《中国循证心血管医学杂志》
2019年第8期986-988,991,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词
灯盏生脉胶囊
不稳定型心绞痛
临床疗效
生活质量
Dengzhan Shenmai Capsules
Unstable angina pectoris
Clinical efficacy
Quality of life
